Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Randomized, Placebo-Controlled, Observer Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Self-Amplifying MRNA Influenza Vaccine in Healthy Adults

NCT06028347 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT06028347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06028347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Randomized, Placebo-Controlled, Observer Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Self-Amplifying MRNA Influenza Vaccine in Healthy Adults
Lead sponsor
Seqirus
Phase
Phase 1
Overall status
Completed
Start date
October 5, 2023
Completion date
October 13, 2024
Enrollment
96 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human